ALNYLAM PHARMACEUTICALS, INC. Variable Lease, Cost
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Variable Lease, Cost of $24.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2019-12-31 was $2.22M.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2019-09-30 was $3.46M.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2019-06-30 was $4.49M.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2019-03-31 was $5.05M.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for fiscal 2025 was $24.55M, a 24.26% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for fiscal 2024 was $19.76M, a 2.57% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for fiscal 2023 was $20.28M, a 15.12% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. variable lease, cost for fiscal 2022 was $17.61M, a 3.60% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $24.55M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $19.76M 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $20.28M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $17.61M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $18.27M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $11.05M 10-K · filed 2022-02-10 | |||
| 2019-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $5.68M derived: sum of 2 quarters · filed 2021-02-11 | $10.16M derived: sum of 3 quarters · filed 2021-02-11 | $15.21M 10-K · filed 2021-02-11 |
| 2019-09-30 | $3.46M 10-Q · filed 2019-10-31 | $7.95M derived: sum of 2 quarters · filed 2019-10-31 | $12.99M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $4.49M 10-Q · filed 2019-08-06 | $9.53M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $5.05M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |